This means that the formaldehyde content in the vaccine is 180—250 times the upper limit set by the Chinese Pharmacopoeia.
The greatest increases were seen with a heterologous booster, resulting in 96% effectiveness against hospitalization and 93% against symptomatic disease.
Both vaccines induced SARS-CoV-2-specific CD4+ and CD8+ T-cell responses at one-month post-vaccination but CoronaVac elicited significantly higher structural protein-specific CD4+ and CD8+ T-cell responses.